P
erceptive Informatics has strengthened its capacity for processing and analysing medical images in central nervous system (CNS) and oncology clinical trials through an alliance with Canadian company Biospective.
Perceptive, the eClinical solutions subsidiary of US-based contract research organisation Parexel International, will supplement its existing medical imaging technology with Biospective’s specialised imaging process and analysis software, tailored for CNS and oncology studies and including Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) techniques.
The enhanced capabilities will be used to support independent reviews of imaging data for both exploratory and large-scale multicentre clinical trials. Perceptive Informatics’ Medical Imaging Group is a global operation that services a wide range of therapeutic areas including oncology, the CNS, musculoskeletal conditions, cardiovascular disease and metabolism/endocrinology.
“With CNS and oncology research growing at a fast pace, Perceptive Informatics is focused on expanding its capabilities to help clients use medical imaging as an endpoint, or biomarker, to assess efficacy and safety of new treatments in these important therapeutic areas,” said Dr Kenneth Faulkner, vice president of medical imaging for Perceptive Informatics.
Based in Montreal, Biospective specialises in pre-clinical and clinical assessments of novel anti-cancer and CNS disease therapeutics using a broad range of biomarkers.
